Recent research advances about vortioxetine: a novel multimodal antidepressant
10.3760/cma.j.cn113661-20210219-00086
- VernacularTitle:新型多模式作用抗抑郁药伏硫西汀的研究进展
- Author:
Xiaofen ZONG
1
;
Maolin HU
1
;
Gaohua WANG
1
Author Information
1. 武汉大学人民医院精神科 430061
- Publication Type:Journal Article
- Keywords:
Major depressive disorder;
Vortioxetine;
Cognitive function
- From:
Chinese Journal of Psychiatry
2021;54(6):480-484
- CountryChina
- Language:Chinese
-
Abstract:
Vortioxetine was approved by the US FDA in 2013 and by China Food and Drug Administration in November 2017 for the treatment of major depressive disorder (MDD) in adults. Vortioxetine exerts antidepressant effects by inhibiting 5-HT transporter-mediated 5-HT reuptake and regulating the activity of multiple 5-HT receptors. Vitro and animal studies have shown that, in addition to increasing 5-HT concentrations, vortioxetine elevates dopamine, norepinephrine, acetylcholine, histamine, and glutamate neurotransmission and decreases GABA neurotransmission in some brain areas associated with MDD. Clinical studies indicate that vortioxetine can relieve multidimensional symptoms, improve cognitive functions, and promote the recovery of social function in MDD patients. This article comprehensively reviews vortioxetine for the treatment of depression in aspects of the mechanism of action, clinical efficacy and safety, real-world studies, and clinical application.
